{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T17:59:47Z","timestamp":1770659987608,"version":"3.49.0"},"reference-count":32,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2008,1,21]],"date-time":"2008-01-21T00:00:00Z","timestamp":1200873600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2008,2]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma. Its activity is believed to be due modulation of the tumour milieu, including downregulation of angiogenesis and inflammatory cytokines. Between July 2001 and April 2004, 24 patients with relapsed\/refractory indolent lymphomas received thalidomide 200\u2003mg daily with escalation by 100\u2003mg daily every 1\u20132\u2003weeks as tolerated, up to a maximum of 800\u2003mg daily. Patients had received a median of 2 (range, 1\u20134) prior regimens. Of 24 evaluable patients, two achieved a complete remission and one achieved a partial remission for an overall response rate of 12\u00b75% (95% confidence interval: 2\u00b76\u201332\u00b74%). Eleven patients progressed during therapy. Grade 3\u20134 adverse effects included myelosuppression, fatigue, somnolence\/depressed mood, neuropathy and dyspnea. Of concern was the occurrence of four thromboembolic events. Our results failed to demonstrate an important response rate to single agent thalidomide in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent, lenalidomide.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2007.06937.x","type":"journal-article","created":{"date-parts":[[2008,2,6]],"date-time":"2008-02-06T02:56:06Z","timestamp":1202266566000},"page":"313-319","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Thalidomide has limited single\u2010agent activity in relapsed or refractory indolent non\u2010Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B"],"prefix":"10.1111","volume":"140","author":[{"given":"Sonali M.","family":"Smith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Grinblatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey L.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna","family":"Niedzwiecki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Rizzieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy L.","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce D.","family":"Cheson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the Cancer and Leukemia Group B","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,1,21]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.11.2471"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2005.10.001"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2006.00784.x"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(02)01300-1"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01547.x"},{"key":"e_1_2_5_7_1","doi-asserted-by":"crossref","first-page":"306a","DOI":"10.1182\/blood.V108.11.306.306","article-title":"Clinical efficacy of lenalidomide {revlimid\u00ae} in patients with relapsed or refractory chronic lymphocytic leukemia (CLL): updated results of a phase II clinical trial","volume":"108","author":"Chanan\u2010Khan A.","year":"2006","journal-title":"Blood"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.9.4082"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403058"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.1.210"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600607"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1204623"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20625"},{"key":"e_1_2_5_15_1","first-page":"583","article-title":"Nonparametric estimation from incomplete observations","volume":"47","author":"Kaplan E.","year":"1958","journal-title":"Journal of the American Statistical Association"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-1091"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22239"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190600799631"},{"key":"e_1_2_5_19_1","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1182\/blood.V100.6.2263","article-title":"Polymorphisms of the tumor necrosis factor\u2010alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma","volume":"100","author":"Neben K.","year":"2002","journal-title":"Blood"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.02059.x"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20070"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-015909"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(05)70434-4"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1204"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.12.3712"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.2179"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1286-4579(02)01645-3"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6446(04)03307-0"},{"key":"e_1_2_5_29_1","doi-asserted-by":"crossref","first-page":"531a","DOI":"10.1182\/blood.V108.11.531.531","article-title":"Preliminary results from a phase II study of lenalidomide monotherapy in relapsed\/refractory aggressive non\u2010Hodgkin\u2019s lymphoma","volume":"108","author":"Wiernik P.H.","year":"2006","journal-title":"Blood"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03810.x"},{"key":"e_1_2_5_31_1","doi-asserted-by":"crossref","first-page":"2482a","DOI":"10.1182\/blood.V108.11.2482.2482","article-title":"Early results from a phase II study of lenalidomide monotherapy in relapsed\/refractory indolent non\u2010Hodgkin\u2019s lymphoma","volume":"108","author":"Witzig T.E.","year":"2006","journal-title":"Blood"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.9.5084"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0407541101"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2007.06937.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2007.06937.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T07:23:45Z","timestamp":1697441025000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2007.06937.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,21]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["10.1111\/j.1365-2141.2007.06937.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2007.06937.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,21]]},"assertion":[{"value":"2008-01-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}